Literature DB >> 33827588

Ethical and legal issues in psychedelic harm reduction and integration therapy.

Brian Pilecki1, Jason B Luoma2, Geoff J Bathje3, Joseph Rhea4, Vilmarie Fraguada Narloch5.   

Abstract

Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated strong evidence of their therapeutic benefits. While psychedelics are currently prohibited substances in most countries, the growing popularity of their therapeutic potential is leading many people to use psychedelics on their own rather than waiting for legal medical access. Therapists therefore have an ethical duty to meet this need by providing support for clients using psychedelics. However, incorporating psychedelics into traditional psychotherapy poses some risk given their prohibited status and many therapists are unsure of how they might practice in this area. This paper explicates such risks and describes ways in which therapists can mitigate them and strive to practice within legal and ethical boundaries. A harm reduction approach will be emphasized as a useful framework for conducting therapy around clients' use of psychedelics. It is argued that therapists can meet with clients before and after their own personal psychedelic experiences in order to help clients minimize risk and maximize benefit. Common clinical scenarios in this growing clinical area will also be discussed.

Entities:  

Keywords:  Harm reduction; Psychedelic integration; Psychedelic-assisted therapy; Psychedelics

Year:  2021        PMID: 33827588     DOI: 10.1186/s12954-021-00489-1

Source DB:  PubMed          Journal:  Harm Reduct J        ISSN: 1477-7517


  25 in total

1.  Mescaline use for 5700 years.

Authors:  Jan G Bruhn; Peter A G M De Smet; Hesham R El-Seedi; Olof Beck
Journal:  Lancet       Date:  2002-05-25       Impact factor: 79.321

2.  Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials.

Authors:  Teri S Krebs; Pål-Ørjan Johansen
Journal:  J Psychopharmacol       Date:  2012-03-08       Impact factor: 4.153

3.  Hallucinogens of plant origin.

Authors:  R E Schultes
Journal:  Science       Date:  1969-01-17       Impact factor: 47.728

4.  New records of mushroom stones from Guatemala.

Authors:  B Lowy
Journal:  Mycologia       Date:  1971 Sep-Oct       Impact factor: 2.696

Review 5.  Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.

Authors:  Matthew W Johnson; Peter S Hendricks; Frederick S Barrett; Roland R Griffiths
Journal:  Pharmacol Ther       Date:  2018-12-04       Impact factor: 12.310

6.  Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.

Authors:  Roland R Griffiths; Matthew W Johnson; Michael A Carducci; Annie Umbricht; William A Richards; Brian D Richards; Mary P Cosimano; Margaret A Klinedinst
Journal:  J Psychopharmacol       Date:  2016-12       Impact factor: 4.153

7.  Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.

Authors:  R L Carhart-Harris; M Bolstridge; C M J Day; J Rucker; R Watts; D E Erritzoe; M Kaelen; B Giribaldi; M Bloomfield; S Pilling; J A Rickard; B Forbes; A Feilding; D Taylor; H V Curran; D J Nutt
Journal:  Psychopharmacology (Berl)       Date:  2017-11-08       Impact factor: 4.530

8.  Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.

Authors:  Alicia L Danforth; Charles S Grob; Christopher Struble; Allison A Feduccia; Nick Walker; Lisa Jerome; Berra Yazar-Klosinski; Amy Emerson
Journal:  Psychopharmacology (Berl)       Date:  2018-09-08       Impact factor: 4.530

9.  Effects of Schedule I drug laws on neuroscience research and treatment innovation.

Authors:  David J Nutt; Leslie A King; David E Nichols
Journal:  Nat Rev Neurosci       Date:  2013-06-12       Impact factor: 34.870

10.  Over 30 million psychedelic users in the United States.

Authors:  Teri S Krebs; Pål-Ørjan Johansen
Journal:  F1000Res       Date:  2013-03-28
View more
  5 in total

Review 1.  Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines.

Authors:  Sean J Belouin; Lynnette A Averill; Jack E Henningfield; Stephen N Xenakis; Ingrid Donato; Charles S Grob; Ann Berger; Veronica Magar; Alicia L Danforth; Brian T Anderson
Journal:  Neuropharmacology       Date:  2022-08-13       Impact factor: 5.273

Review 2.  New Paradigms of Old Psychedelics in Schizophrenia.

Authors:  Danish Mahmood; Sattam K Alenezi; Md Jamir Anwar; Faizul Azam; Kamal A Qureshi; Mariusz Jaremko
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-23

3.  The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences.

Authors:  Tomas Frymann; Sophie Whitney; David B Yaden; Joshua Lipson
Journal:  Front Psychol       Date:  2022-05-23

Review 4.  The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice.

Authors:  Cindy A Stein; Andrew Penn; Stephanie Van Hope; Caroline G Dorsen; Mariavittoria Mangini
Journal:  J Midwifery Womens Health       Date:  2022-05-06       Impact factor: 2.891

5.  Are you tripping comfortably? Investigating the relationship between harm reduction and the psychedelic experience.

Authors:  Madelene Palmer; Olivia M Maynard
Journal:  Harm Reduct J       Date:  2022-07-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.